|
Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript
Seeking Alpha On the next program, I would like to talk about is PL-3994, our natriuretic peptide receptor agonist in development as a treatment for acute exacerbations of asthma. Acute exacerbations of asthma, also called acute severe asthma, is an ongoing asthma … Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results |
View full post on asthma – Google News